Prophylactic cranial irradiation in extensive small-cell lung cancer.
AuthorsSlotman, Berend J
Rankin, Elaine M
Postmus, Pieter E
AffiliationDepartment of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. firstname.lastname@example.org
MetadataShow full item record
AbstractBACKGROUND: We conducted a randomized trial of prophylactic cranial irradiation in patients with extensive small-cell lung cancer who had had a response to chemotherapy. METHODS: Patients between the ages of 18 and 75 years with extensive small-cell lung cancer were randomly assigned to undergo prophylactic cranial irradiation (irradiation group) or receive no further therapy (control group). The primary end point was the time to symptomatic brain metastases. Computed tomography or magnetic resonance imaging of the brain was performed when any predefined key symptom suggestive of brain metastases was present. RESULTS: The two groups (each with 143 patients) were well balanced regarding baseline characteristics. Patients in the irradiation group had a lower risk of symptomatic brain metastases (hazard ratio, 0.27; 95% confidence interval [CI], 0.16 to 0.44; P<0.001). The cumulative risk of brain metastases within 1 year was 14.6% in the irradiation group (95% CI, 8.3 to 20.9) and 40.4% in the control group (95% CI, 32.1 to 48.6). Irradiation was associated with an increase in median disease-free survival from 12.0 weeks to 14.7 weeks and in median overall survival from 5.4 months to 6.7 months after randomization. The 1-year survival rate was 27.1% (95% CI, 19.4 to 35.5) in the irradiation group and 13.3% (95% CI, 8.1 to 19.9) in the control group. Irradiation had side effects but did not have a clinically significant effect on global health status. CONCLUSIONS: Prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs disease-free and overall survival. (ClinicalTrials.gov number, NCT00016211 [ClinicalTrials.gov].).
CitationProphylactic cranial irradiation in extensive small-cell lung cancer. 2007, 357 (7):664-72 N. Engl. J. Med.
JournalThe New England Journal of Medicine
- Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.
- Authors: Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J
- Issue date: 1999 Aug 12
- Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
- Authors: Chen GY, Jiang GL, Wang LJ, Qian H, Fu XL, Yang H, Wu KL, Zhao S
- Issue date: 2005 Jan 1
- Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
- Authors: Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K
- Issue date: 1994 Oct
- [Sequential treatment of VmP regimen and whole brain radiotherapy for small cell lung cancer patients with brain metastases].
- Authors: Yue X, Zang QC
- Issue date: 2004 Dec
- [Patterns of relapse in patients with small cell lung cancer--the effect of chest irradiation and prophylactic cranial irradiation combined with intensive chemotherapy on long-term survival].
- Authors: Ueoka H, Ohnoshi T, Numata T, Kawahara S, Nishii K, Yonei T, Yamashita H, Moritaka T, Kiura K, Uji H
- Issue date: 1990 Dec